ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Diisopropylcarbodiimide → [2-(ethyldisulfanyl)-6-methylphenyl] (3S)-3-[[(2S)-2-[[(2S)-3-methyl-2-[methyl-[(2S)-4-methyl-2-[methyl-[2-[[(2S)-2-[methyl-[(2S,3R)-2-[[(2S)-4-methyl-2-[methyl-[(2S)-3-methyl-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]butanoyl]amino]pentanoyl]amino]-3-trityloxybutanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]pentanoyl]amino]butanoyl]amino]-3-phenylpropanoyl]amino]-4-[methyl-[(2S)-1-oxo-1-[[(2S)-1-oxo-1-piperidin-1-ylpropan-2-yl]amino]-3-phenylpropan-2-yl]amino]-4-oxobutanoate

HRID 1482257
印刷

反応式

HRID 1482257 の反応式
[CH2:1]([S:3][S:4][C:5]1[CH:10]=[CH:9][CH:8]=[C:7]([CH3:11])[C:6]=1[OH:12])[CH3:2].C(=NC(C)C)=NC(C)C.[CH2:22]([C@@H:29]([C:86](=[O:150])[NH:87][CH2:88][C:89](=[O:149])[N:90]([CH3:148])[C@@H:91]([CH2:144][CH:145]([CH3:147])[CH3:146])[C:92](=[O:143])[N:93]([CH3:142])[C@@H:94]([CH:139]([CH3:141])[CH3:140])[C:95](=[O:138])[NH:96][C@@H:97]([CH2:131][C:132]1[CH:137]=[CH:136][CH:135]=[CH:134][CH:133]=1)[C:98](=[O:130])[NH:99][C@H:100]([C:105](=[O:129])[N:106]([CH3:128])[C@@H:107]([CH2:121][C:122]1[CH:127]=[CH:126][CH:125]=[CH:124][CH:123]=1)[C:108](=[O:120])[NH:109][C@@H:110]([CH3:119])[C:111](=[O:118])[N:112]1[CH2:117][CH2:116][CH2:115][CH2:114][CH2:113]1)[CH2:101][C:102](O)=[O:103])[N:30]([CH3:85])[C:31](=[O:84])[C@H:32]([C@H:62]([O:64][C:65]([C:78]1[CH:83]=[CH:82][CH:81]=[CH:80][CH:79]=1)([C:72]1[CH:77]=[CH:76][CH:75]=[CH:74][CH:73]=1)[C:66]1[CH:71]=[CH:70][CH:69]=[CH:68][CH:67]=1)[CH3:63])[NH:33][C:34](=[O:61])[C@H:35]([CH2:57][CH:58]([CH3:60])[CH3:59])[N:36]([CH3:56])[C:37](=[O:55])[C@H:38]([CH:52]([CH3:54])[CH3:53])[NH:39][C:40](=[O:51])[C@H:41]([CH3:50])[NH:42][C:43](=[O:49])[O:44][C:45]([CH3:48])([CH3:47])[CH3:46])[C:23]1[CH:28]=[CH:27][CH:26]=[CH:25][CH:24]=1>CN(C)C1C=CN=CC=1.ClCCl>[CH2:22]([C@@H:29]([C:86](=[O:150])[NH:87][CH2:88][C:89](=[O:149])[N:90]([CH3:148])[C@@H:91]([CH2:144][CH:145]([CH3:147])[CH3:146])[C:92](=[O:143])[N:93]([CH3:142])[C@@H:94]([CH:139]([CH3:141])[CH3:140])[C:95](=[O:138])[NH:96][C@@H:97]([CH2:131][C:132]1[CH:137]=[CH:136][CH:135]=[CH:134][CH:133]=1)[C:98](=[O:130])[NH:99][C@H:100]([C:105](=[O:129])[N:106]([CH3:128])[C@@H:107]([CH2:121][C:122]1[CH:123]=[CH:124][CH:125]=[CH:126][CH:127]=1)[C:108](=[O:120])[NH:109][C@@H:110]([CH3:119])[C:111](=[O:118])[N:112]1[CH2:117][CH2:116][CH2:115][CH2:114][CH2:113]1)[CH2:101][C:102]([O:12][C:6]1[C:7]([CH3:11])=[CH:8][CH:9]=[CH:10][C:5]=1[S:4][S:3][CH2:1][CH3:2])=[O:103])[N:30]([CH3:85])[C:31](=[O:84])[C@H:32]([C@H:62]([O:64][C:65]([C:66]1[CH:71]=[CH:70][CH:69]=[CH:68][CH:67]=1)([C:72]1[CH:73]=[CH:74][CH:75]=[CH:76][CH:77]=1)[C:78]1[CH:83]=[CH:82][CH:81]=[CH:80][CH:79]=1)[CH3:63])[NH:33][C:34](=[O:61])[C@H:35]([CH2:57][CH:58]([CH3:60])[CH3:59])[N:36]([CH3:56])[C:37](=[O:55])[C@H:38]([CH:52]([CH3:54])[CH3:53])[NH:39][C:40](=[O:51])[C@H:41]([CH3:50])[NH:42][C:43](=[O:49])[O:44][C:45]([CH3:46])([CH3:47])[CH3:48])[C:23]1[CH:28]=[CH:27][CH:26]=[CH:25][CH:24]=1
参加物実験手順後処理出典と根拠反応ノート

参加物

6

反応物 3

HCID 12734DiisopropylcarbodiimideHCID 896685262-(Ethyldisulfanyl)-6-methylphenolHCID 117735990(6S,9S,12S,15S,18S,24S,27S,30S,33S)-18,30-dibenzyl-12,24-diisobutyl-9,27-diisopropyl-2,2,6,11,17,23,26-heptamethyl-33-(methyl((S)-1-oxo-1-(((S)-1-oxo-1-(piperidin-1-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)carbamoyl)-4,7,10,13,16,19,22,25,28,31-decaoxo-15-((R)-1-(trityloxy)ethyl)-3-oxa-5,8,11,14,17,20,23,26,29,32-decaazapentatriacontan-35-oic acid

生成物 1

HCID 131736694
[2-(ethyldisulfanyl)-6-methylphenyl] (3S)-3-[[(2S)-2-[[(2S)-3-methyl-2-[methyl-[(2S)-4-methyl-2-[methyl-[2-[[(2S)-2-[methyl-[(2S,3R)-2-[[(2S)-4-methyl-2-[methyl-[(2S)-3-methyl-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]butanoyl]amino]pentanoyl]amino]-3-trityloxybutanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]pentanoyl]amino]butanoyl]amino]-3-phenylpropanoyl]amino]-4-[methyl-[(2S)-1-oxo-1-[[(2S)-1-oxo-1-piperidin-1-ylpropan-2-yl]amino]-3-phenylpropan-2-yl]amino]-4-oxobutanoate
収率 80%

試薬・触媒・溶媒 2

HCID 142844-(Dimethylamino)pyridine触媒HCID 6344Dichloromethane溶媒

実験手順

2-(Ethyldisulfanyl)-6-methylphenol separately synthesized according to a conventional method (J. AM. CHEM. SOC. 2009, 131, 5432-5437) (10.3 mg, 0.051 mmol), N,N′-methanediylidenebis(propan-2-amine) (8.0 ul, 0.051 mmol) and N,N-dimethylpyridin-4-amine (4.2 mg, 0.034 mmol) were added to a solution of (6S,9S,12S,15S,18S,24S,27S,30S,33S)-18,30-dibenzyl-12,24-diisobutyl-9,27-diisopropyl-2,2,6,11,17,23,26-heptamethyl-33-(methyl((S)-1-oxo-1-(((S)-1-oxo-1-(piperidin-1-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)carbamoyl)-4,7,10,13,16,19,22,25,28,31-decaoxo-15-((R)-1-(trityloxy)ethyl)-3-oxa-5,8,11,14,17,20,23,26,29,32-decaazapentatriacontan-35-oic acid (Boc-Ala-Val-MeLeu-Thr(Trt)-MePhe-Gly-MeLeu-MeVal-Phe-Asp-MePhe-Ala-piperidine, 60.9 mg, 0.034 mmol) synthesized by peptide synthesis by the Fmoc method previously described using Boc amino acid in place of Fmoc amino acid at the N-terminal in dichloromethane (300 ul), and the mixture was stirred at room temperature overnight. The reaction solution was then concentrated under reduced pressure and purified by reverse phase silica gel column chromatography (10 mM aqueous ammonium acetate solution/methanol=70/30→0/100) to afford 2-(ethyldisulfanyl)-6-methylphenyl (6S,9S,12S,15S,18S,24S,27S,30S,33S)-18,30-dibenzyl-12,24-diisobutyl-9,27-diisopropyl-2,2,6,11,17,23,26-heptamethyl-33-(methyl((S)-1-oxo-1-(((S)-1-oxo-1-(piperidin-1-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)carbamoyl)-4,7,10,13,16,19,22,25,28,31-decaoxo-15-((R)-1-(trityloxy)ethyl)-3-oxa-5,8,11,14,17,20,23,26,29,32-decaazapentatriacontan-35-oate (Compound P-138) (53.8 mg, 80%).

後処理

  1. concentrationThe reaction solution was then concentrated under reduced pressure
  2. custompurified by reverse phase silica gel column chromatography (10 mM aqueous ammonium acetate solution/methanol=70/30→0/100)

出典と根拠

ORDレコード
ord-452d4f10fbc649eb9a411ddd1a39a591
出典データセット
uspto-grants-2016_08
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US09409952B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート